journal article·2023-07Open access

A Nanovaccine Based on Adjuvant Peptide FK‐13 and l‐Phenylalanine Poly(ester amide) Enhances CD8+ T Cell‐Mediated Antitumor Immunity

Chunyuan Xie, Xinru You, Hongxia Zhang, Jiahui Li, Liying Wang, Yongxiang Liu, Zining Wang, Ruhui Yao, Tong Tong, Mengyun Li, Xiaojuan Wang, Lei Cui, Huanling Zhang, Hui Guo, Chunwei Li, Jun Wu, Xiaojun Xia

Advanced Science· Volume 10· Issue 20

Abstract

Abstract Cancer vaccines have shown promise as effective means of antitumor immunotherapy by inducing tumor antigen‐specific T cell immunity. In this study, a novel peptide‐based tumor nanovaccine that boosts antigen presentation and elicits effective antitumor immunity is developed. The adjuvant characteristics of an antimicrobial peptide‐derived core peptide, FK‐13, are investigated and used it to generate a fusion peptide named FK‐33 with tumor antigen epitopes. l‐phenylalanine‐based poly(ester amide) (Phe‐PEA), 8p4, is also identified as a competent delivery vehicle for the fusion peptide FK‐33. Notably, the vaccination of 8p4 + FK‐33 nanoparticles (8FNs) in vivo induces dendritic cell activation in the lymph nodes and elicits robust tumor antigen‐specific CD8+ T cell response. The nanovaccine 8FNs demonstrate significant therapeutic and prophylactic efficacy against in situ tumor growth, effectively inhibit tumor metastasis, and significantly prolong the survival of tumor‐bearing mice. Moreover, 8FNs can incorporate different tumor antigens and exhibit a synergistic therapeutic effect with antiprogrammed cell death protein 1 (PD‐1) therapy. In summary, 8FNs represent a promising platform for personalized cancer vaccines and may serve as a potential combinational modality to improve current immunotherapy.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Immunotherapy and Immune Responses · RNA Interference and Gene Delivery · Cancer Immunotherapy and Biomarkers

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine Sun Yat‐sen University Cancer Center 651 Dongfeng East Road Guangzhou 510060 China

Center for Nanomedicine and Department of Anesthesiology Brigham and Women's Hospital Harvard Medical School Boston MA 02115 USA

School of Food Science and Technology National Engineering Research Center of Seafood Dalian Polytechnic University Dalian 116024 China

School of Biomedical Engineering Sun Yat‐sen University 66 Gongchang Road Shenzhen 518107 China

State Key Laboratory of Biocontrol School of Life Science Sun Yat‐sen University 135 Xingang West Road Guangzhou 510275 China

Bioscience and Biomedical Engineering Thrust The Hong Kong University of Science and Technology (Guangzhou) Nansha Guangzhou 511400 China

Division of Life Science The Hong Kong University of Science and Technology Hong Kong SAR 999077 China

Funding

National Natural Science Foundation of China · Guangdong Innovative and Entrepreneurial Research Team Program · Fundamental Research Funds for the Central Universities · China Postdoctoral Science Foundation

References (53)

Show source-provided references
1. 10.1038/s41577-019-0218-410.1038/s41577-019-0218-4 ↗
2. 10.1016/j.ccell.2020.07.00410.1016/j.ccell.2020.07.004 ↗
3. 10.1126/science.aaa817210.1126/science.aaa8172 ↗
4. 10.1007/s11523-020-00788-w10.1007/s11523-020-00788-w ↗
5. 10.1038/natrevmats.2015.810.1038/natrevmats.2015.8 ↗
6. 10.1126/science.aar711210.1126/science.aar7112 ↗
7. 10.1002/smll.20220110810.1002/smll.202201108 ↗
8. 10.1016/j.biotechadv.2017.05.00210.1016/j.biotechadv.2017.05.002 ↗
9. 10.1038/nmat482210.1038/nmat4822 ↗
10. 10.1038/nature2299110.1038/nature22991 ↗
11. 10.1021/acs.chemrev.9b0047210.1021/acs.chemrev.9b00472 ↗
12. 10.1038/nrc.2016.1610.1038/nrc.2016.16 ↗
13. 10.1038/nri.2017.13110.1038/nri.2017.131 ↗
14. 10.1002/adma.20120044610.1002/adma.201200446 ↗
15. 10.1038/nnano.2017.5210.1038/nnano.2017.52 ↗
16. 10.1021/acsnano.5b0675010.1021/acsnano.5b06750 ↗
17. 10.1002/anie.20150617910.1002/anie.201506179 ↗
18. 10.1038/s41587-019-0390-x10.1038/s41587-019-0390-x ↗
19. 10.1016/j.immuni.2010.10.00210.1016/j.immuni.2010.10.002 ↗
20. 10.1038/s41573-021-00163-y10.1038/s41573-021-00163-y ↗
21. 10.4049/jimmunol.172.2.114610.4049/jimmunol.172.2.1146 ↗
22. 10.1002/eji.20144498810.1002/eji.201444988 ↗
23. 10.1080/2162402X.2019.160810610.1080/2162402X.2019.1608106 ↗
24. 10.1021/ja058487510.1021/ja0584875 ↗
25. Engelberg Y. · Nat. Commun. · 2020 · 11
26. 10.1016/j.bbapap.2016.02.01310.1016/j.bbapap.2016.02.013 ↗
27. 10.3389/fphar.2018.0011810.3389/fphar.2018.00118 ↗
28. 10.1016/j.actbio.2012.07.02710.1016/j.actbio.2012.07.027 ↗
29. 10.1172/JCI12747110.1172/JCI127471 ↗
30. 10.1038/s41577-018-0029-z10.1038/s41577-018-0029-z ↗
31. 10.1016/j.immuni.2021.08.02610.1016/j.immuni.2021.08.026 ↗
32. 10.1038/s41590-020-00810-310.1038/s41590-020-00810-3 ↗
33. 10.1016/j.nano.2018.09.00410.1016/j.nano.2018.09.004 ↗
34. 10.1002/advs.20210413410.1002/advs.202104134 ↗
35. 10.1002/advs.20190292610.1002/advs.201902926 ↗
36. 10.1038/s41551-018-0284-010.1038/s41551-018-0284-0 ↗
37. 10.1084/jem.2005244210.1084/jem.20052442 ↗
38. 10.1038/s41577-019-0210-z10.1038/s41577-019-0210-z ↗
39. 10.1073/pnas.180069511510.1073/pnas.1800695115 ↗
40. 10.1038/nrd.2018.16910.1038/nrd.2018.169 ↗
41. 10.1016/j.ymthe.2017.11.00910.1016/j.ymthe.2017.11.009 ↗
42. 10.1016/j.cell.2011.09.02410.1016/j.cell.2011.09.024 ↗
43. 10.1038/s41568-021-00346-010.1038/s41568-021-00346-0 ↗
44. 10.1038/s41591-020-01206-410.1038/s41591-020-01206-4 ↗
45. 10.1038/s41586-018-0792-910.1038/s41586-018-0792-9 ↗
46. 10.1172/JCI13491510.1172/JCI134915 ↗
47. 10.1177/175342591561064310.1177/1753425915610643 ↗
48. Mori T. · Int. J. Mol. Sci. · 2021 · 22
49. 10.1038/s41467-020-17736-x10.1038/s41467-020-17736-x ↗
50. 10.1039/C4RA13007C10.1039/C4RA13007C ↗
51. 10.3389/fimmu.2018.0305910.3389/fimmu.2018.03059 ↗
52. 10.1080/14760584.2021.198489010.1080/14760584.2021.1984890 ↗
53. 10.1126/sciadv.aax228510.1126/sciadv.aax2285 ↗